Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received final approval from the USFDA for Niacin Extended-Release Tablets USP in three strengths — 500 mg, 750 mg, and 1,000 mg. Niacin is used to manage cholesterol levels and reduce the risk of cardiovascular disease. This final approval allows the company to commercially launch the product in the US market. The approval adds another product to Zydus's growing US generics portfolio.
This is a positive development as it strengthens Zydus's US formulations business and opens up a new revenue stream. Investors typically view USFDA approvals favorably, though the actual impact will depend on the product's market size and competition.